BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 28601944)

  • 1. Glucocorticoid-induced leucine zipper expression is associated with response to treatment and immunoregulation in systemic lupus erythematosus.
    Mohammadi S; Ebadpour MR; Sedighi S; Saeedi M; Memarian A
    Clin Rheumatol; 2017 Aug; 36(8):1765-1772. PubMed ID: 28601944
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Glucocorticoid-induced leucine zipper (GILZ) inhibits B cell activation in systemic lupus erythematosus.
    Jones SA; Toh AE; Odobasic D; Oudin MA; Cheng Q; Lee JP; White SJ; Russ BE; Infantino S; Light A; Tarlinton DM; Harris J; Morand EF
    Ann Rheum Dis; 2016 Apr; 75(4):739-47. PubMed ID: 26612340
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association of plasma B lymphocyte stimulator levels and disease activity in systemic lupus erythematosus.
    Petri M; Stohl W; Chatham W; McCune WJ; Chevrier M; Ryel J; Recta V; Zhong J; Freimuth W
    Arthritis Rheum; 2008 Aug; 58(8):2453-9. PubMed ID: 18668552
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Aberrant expression of regulatory cytokine IL-35 in patients with systemic lupus erythematosus.
    Cai Z; Wong CK; Kam NW; Dong J; Jiao D; Chu M; Lam CW; Tam LS
    Lupus; 2015 Oct; 24(12):1257-66. PubMed ID: 25966926
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interferon-α-induced B-lymphocyte stimulator expression and mobilization in healthy and systemic lupus erthymatosus monocytes.
    López P; Scheel-Toellner D; Rodríguez-Carrio J; Caminal-Montero L; Gordon C; Suárez A
    Rheumatology (Oxford); 2014 Dec; 53(12):2249-58. PubMed ID: 24942493
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Elevated gene expression of Th1/Th2 associated transcription factors is correlated with disease activity in patients with systemic lupus erythematosus.
    Lit LC; Wong CK; Li EK; Tam LS; Lam CW; Lo YM
    J Rheumatol; 2007 Jan; 34(1):89-96. PubMed ID: 17117487
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Increased interferon-1α, interleukin-10 and BLyS concentrations as clinical activity biomarkers in systemic lupus erythematosus.
    Fernández Matilla M; Grau García E; Fernández-Llanio Comella N; Chalmeta Verdejo I; Ivorra Cortés J; Castellano Cuesta JA; Román Ivorra JA
    Med Clin (Barc); 2019 Sep; 153(6):225-231. PubMed ID: 30795903
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of baseline BLyS levels and type 1 interferon-inducible gene signature status in determining belimumab response in systemic lupus erythematosus: a post hoc meta-analysis.
    Wilkinson C; Henderson RB; Jones-Leone AR; Flint SM; Lennon M; Levy RA; Ji B; Bass DL; Roth D
    Arthritis Res Ther; 2020 May; 22(1):102. PubMed ID: 32366280
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Could GILZ Be the Answer to Glucocorticoid Toxicity in Lupus?
    Flynn JK; Dankers W; Morand EF
    Front Immunol; 2019; 10():1684. PubMed ID: 31379872
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Excessive production of IFN-gamma in patients with systemic lupus erythematosus and its contribution to induction of B lymphocyte stimulator/B cell-activating factor/TNF ligand superfamily-13B.
    Harigai M; Kawamoto M; Hara M; Kubota T; Kamatani N; Miyasaka N
    J Immunol; 2008 Aug; 181(3):2211-9. PubMed ID: 18641361
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cytokine imbalance in systemic lupus erythematosus: a study on northern Indian subjects.
    Arora V; Verma J; Marwah V; Kumar A; Anand D; Das N
    Lupus; 2012 May; 21(6):596-603. PubMed ID: 22300832
    [TBL] [Abstract][Full Text] [Related]  

  • 12. GILZ regulates type I interferon release and sequesters STAT1.
    Nataraja C; Flynn J; Dankers W; Northcott M; Zhu W; Sherlock R; Bennett TJ; Russ BE; Miceli I; Pervin M; D'Cruz A; Harris J; Morand EF; Jones SA
    J Autoimmun; 2022 Jul; 131():102858. PubMed ID: 35810690
    [TBL] [Abstract][Full Text] [Related]  

  • 13. B lymphocyte stimulator expression in pediatric systemic lupus erythematosus and juvenile idiopathic arthritis patients.
    Hong SD; Reiff A; Yang HT; Migone TS; Ward CD; Marzan K; Shaham B; Phei WC; Garza J; Bernstein B; Stohl W
    Arthritis Rheum; 2009 Nov; 60(11):3400-9. PubMed ID: 19877053
    [TBL] [Abstract][Full Text] [Related]  

  • 14. GILZ Regulates the Expression of Pro-Inflammatory Cytokines and Protects Against End-Organ Damage in a Model of Lupus.
    Nataraja C; Dankers W; Flynn J; Lee JPW; Zhu W; Vincent FB; Gearing LJ; Ooi J; Pervin M; Cristofaro MA; Sherlock R; Hasnat MA; Harris J; Morand EF; Jones SA
    Front Immunol; 2021; 12():652800. PubMed ID: 33889157
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gene expression of cytokines (TNF-α, IFN-γ), serum profiles of IL-17 and IL-23 in paediatric systemic lupus erythematosus.
    Rana A; Minz RW; Aggarwal R; Anand S; Pasricha N; Singh S
    Lupus; 2012 Sep; 21(10):1105-12. PubMed ID: 22759859
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Th1/Th2/Th17/Treg cytokine imbalance in systemic lupus erythematosus (SLE) patients: Correlation with disease activity.
    Talaat RM; Mohamed SF; Bassyouni IH; Raouf AA
    Cytokine; 2015 Apr; 72(2):146-53. PubMed ID: 25647269
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Higher activation of the interferon-gamma signaling pathway in systemic lupus erythematosus patients with a high type I IFN score: relation to disease activity.
    Liu M; Liu J; Hao S; Wu P; Zhang X; Xiao Y; Jiang G; Huang X
    Clin Rheumatol; 2018 Oct; 37(10):2675-2684. PubMed ID: 29774490
    [TBL] [Abstract][Full Text] [Related]  

  • 18. B lymphocyte stimulator levels in systemic lupus erythematosus: higher circulating levels in African American patients and increased production after influenza vaccination in patients with low baseline levels.
    Ritterhouse LL; Crowe SR; Niewold TB; Merrill JT; Roberts VC; Dedeke AB; Neas BR; Thompson LF; Guthridge JM; James JA
    Arthritis Rheum; 2011 Dec; 63(12):3931-41. PubMed ID: 22127709
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Elevated BLyS levels in patients with systemic lupus erythematosus: Associated factors and responses to belimumab.
    Roth DA; Thompson A; Tang Y; Hammer AE; Molta CT; Gordon D
    Lupus; 2016 Apr; 25(4):346-54. PubMed ID: 26385220
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of heart rate variability, a marker for cardiac health, on lupus disease activity.
    Thanou A; Stavrakis S; Dyer JW; Munroe ME; James JA; Merrill JT
    Arthritis Res Ther; 2016 Sep; 18(1):197. PubMed ID: 27590046
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.